Drugmakers Eli Lilly and Co. and Boehringer Ingelheim said Friday a European committee has endorsed their type 2 diabetes treatment, linagliptin, a key step toward possible European Union approval.
Lilly, based in Indianapolis, and Boehringer Ingelheim, headquartered in Germany, said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of 5-milligram tablets of the drug. The European Commission, which approves medicines for the European Union, usually makes a decision on these recommendations in two or three months.
For more: Lilly, Boehringer diabetes drug endorsed in Europe - BusinessWeek
No comments:
Post a Comment